Software & SaMD

The Hidden Risk: Gaps in Software Remediation for Medical Devices

June 10, 2025
|
By Dr. Ebot Eyong

As medical devices evolve into software-driven, connected systems, software remediation has become a critical driver of patient safety, regulatory compliance, and commercial success. Yet current frameworks remain fragmented, reactive, and poorly integrated, creating systemic risk and a major opportunity to build regulatory-aware software infrastructure.

Executive Summary

As medical devices evolve into software-driven, connected systems, software remediation has become a critical driver of patient safety, regulatory compliance, and commercial success. Yet current frameworks remain fragmented, reactive, and poorly integrated. This creates systemic risk and a major opportunity to build regulatory-aware software infrastructure.

The Problem

Software is no longer a component of medical devices; it is the device. From AI diagnostics to connected wearables, continuous updates are essential. However, most organizations still rely on legacy quality systems designed for static hardware.The result is a disconnect between real-world software behavior and how remediation is governed, validated, and deployed.

Key Gaps

  • Regulatory ambiguity: Unclear thresholds for “significant changes,” especially for AI systems
  • Weak feedback loops: Limited integration of real-world performance data
  • Poor traceability: Inability to link field issues to code and risk controls
  • Cybersecurity delays: Slow vulnerability response and patch deployment
  • Inefficient change control: Either overly rigid or insufficiently documented
  • Validation gaps: Incomplete regression testing introduces new risks
  • Deployment limitations: Lack of OTA updates slows remediation rollout
  • AI governance gaps: No clear model for adaptive algorithm updates
  • Documentation risks: Inconsistent records drive regulatory findings
  • Communication failures: Low adoption of critical updates in the field

Why This Matters

Regulators are increasing scrutiny on software lifecycle management and AI governance. Companies that fail to modernize face regulatory exposure, slower innovation, and erosion of market trust.

The Opportunity: RegOps

The future lies in regulatory-aware software infrastructure (“RegOps”) that integrates real-time observability, automated traceability, continuous compliance, AI-driven risk detection, and seamless OTA updates.

Conclusion

The industry is running modern software on outdated remediation systems. Solving this gap requires a fundamental redesign of how software, risk, and regulation interact. Those who succeed will not only reduce risk—they will unlock scale.

For more information, visit https://eemedicals.com/

Explore More Publications

Continue exploring Dr. Ebot Eyong’s professional insights on healthcare regulation, FDA submissions, AI-enabled medical devices, quality systems, and global compliance strategy.

Real-World Evidence

Real-World Evidence (RWE) and Biocompatibility: Implications of ISO 10993-1:2025 for Medical Device Manufacturers

December 11, 2025
|
By Dr. Ebot Eyong

The revised ISO 10993-1 marks a significant shift in biocompatibility assessment by enabling risk-based justifications supported by real-world evidence. This article explores pre-market submissions, manufacturer implications, AI-enabled device challenges, and regulatory pitfalls.

Read Article

EU Regulatory Strategy

Case Study: EU MDR Transition Strategy - Remediation

August 13, 2026
|
by Dr. Ebot Eyong

How E&E Medicals Guided a Medical Device Manufacturer Through the Transition from the Medical Device Directive (MDD) to the European Medical Device Regulation (EU MDR 2017/745)

Read Article

Cybersecurity & Cloud Systems

Cloud-Based Systems for Medical Devices: FDA Perspective

April 22, 2024
|
By Dr. Ebot Eyong

The FDA advocates adopting cloud-based systems for medical devices, highlighting benefits such as scalability, enhanced security, collaboration, innovation potential, and operational cost savings. This article explains FDA perspectives and best practices for cloud-based medical device systems.

Read Article

CMC & FDA Submissions

FDA Guidance for Chemistry, Manufacturing, and Controls (CMC) Submissions

January 15, 2025
|
By Dr. Ebot Eyong

The FDA provides several guidance documents for Chemistry, Manufacturing, and Controls submissions, including post-approval manufacturing changes, comparability protocols, disposable manufacturing materials, nanomaterials, and current good manufacturing practice requirements for combination products.

Read Article